Abstract
Question At the time of implementation of human papillomavirus (HPV) vaccine immunization programs, concerns were raised by parents, clinicians, and public health professionals about HPV vaccination possibly leading to riskier sexual health choices among young females. If HPV vaccination influences sexual behaviour among vaccinated females, this might influence the effect of HPV vaccination programs. What is known about the effects of the HPV vaccination program on sexual behaviour among young females?
Answer Human papillomavirus vaccination has not been associated with increased sexual risk behaviour among young females. However, currently available studies have some important limitations, and future studies should focus on a longitudinal design that includes a prevaccination baseline measurement, adjustment for possible confounders, and measurement of both clinical indicators and behavioural outcomes.
Human papillomavirus (HPV) is the most common sexually transmitted infection, with a lifetime risk of acquisition of more than 80% among sexually active female and male populations.1 Human papillomavirus infections are risk factors for developing genital warts, as well as cervical, anal, penile, oropharyngeal, vaginal, and vulvar cancers.2 Primary prevention of HPV-related diseases is possible using HPV vaccines.
HPV vaccination in Canada
Currently all Canadian jurisdictions have implemented school-based HPV vaccination into routine immunization schedules, with uptake rates between 52.6% and 89.3% for at least 1 dose.3,4 At the time of implementation almost a decade ago, parents, clinicians, and public health professionals raised concerns that HPV vaccine programs might lead to riskier sexual health choices among young females.5 For example, in Canada, 21% of parents or guardians of females aged between 8 and 18 had concerns about the potential influence of HPV vaccination on sexual activity.6 Roman Catholic bishops in several provinces opposed HPV vaccination because they believed that abstinence was the “only healthy choice” and vaccination would “send a message that early sexual intercourse is allowed.”7 From a public health perspective, if vaccination did result in a different sexual (risk) behaviour pattern among vaccinated females, this could influence the effectiveness of HPV vaccination programs.8 Therefore, understanding whether HPV vaccination influenced sexual behaviour in young females is an important question for exploration. In the decade since the first HPV immunization programs, data have emerged on the effect of HPV vaccination programs on the sexual behaviour of young females.
Pregnancy and sexually transmitted infection rates
Using pregnancy and sexually transmitted infection (STI) rates as clinical indicators of sexual behaviour, either no association was found with HPV vaccination, or, in some studies, vaccinated young females were less likely to have been pregnant or infected with Chlamydia trachomatis or other STIs (Table 1).3,9–15 In an Ontario-based study, in which outcomes were assessed against a composite outcome of pregnancies and STIs as well as assessed separately, there was no evidence found for an increased risk of pregnancy or STI after HPV vaccination in adolescent girls aged 13 to 17. There was no effect identified when birth cohorts eligible for vaccination were compared with cohorts ineligible for HPV vaccination.3
Several US studies also showed no association between HPV vaccination and STI testing, STI diagnosis, or pregnancy.9–11 Bednarczyk and colleagues reported no increase in the STI and pregnancy rates.9 In another US study, no associations were found between HPV vaccination and receiving STI services in young females (aged 15 to 24 years) who had received the HPV vaccine.10 Furthermore, no associations were found between HPV vaccination and positive STI diagnoses in 2 other US studies and a study from Uganda.12–14 Another study documented a higher rate of C trachomatis diagnosis among young females (aged 14 to 20) not vaccinated for HPV compared with vaccinated young females (19.8% vs 9.5%; odds ratio of 2.30, 95% CI 1.06 to 5.00).15
Behavioural factors
Most studies examining the association between HPV vaccination and self-reported sexual behaviour used a cross-sectional study design (Table 2).8,10,12,14–16 This is not the preferred method for examining the potential effects of the vaccine on sexual behaviour, as it is hard to correct for past behaviour and pre-existing differences between vaccinated and unvaccinated participants, and causal relationships cannot be examined. It is also important to consider the context of these studies. Young females who receive the HPV vaccine are, by definition, different from those who do not get vaccinated, and women (aged ≥ 18 years) have different sexual behaviour than adolescents or girls have.17,18 For this reason, broad inferences should be made with caution. Longitudinal studies offer more reliable findings, but the longitudinal studies available to date have had small sample sizes and might not have had sufficient power to detect changes in sexual behaviour.
In cross-sectional studies among young females (aged 14 to 24), no statistical difference was found in the proportion of females reporting ever having had vaginal intercourse compared with a historical comparable group and an unvaccinated group.10,14 A study including females (aged 16 to 17 years) did not indicate that being offered the HPV vaccine increased the likelihood of having reached sexual debut (41.6% and 41.2% for the group that had not been offered the vaccine and for the group that had been offered the vaccine, respectively). Using a longitudinal study design, comparing vaccinated with unvaccinated participants, the authors did not observe a difference in the change in the proportion of females being sexually active (relative percentage change 8.3% vs 6.0%, adjusted for baseline response and clustering by school).16 In another longitudinal study no differences were observed between vaccinated and unvaccinated girls reporting ever having had sex after adjusting for sociodemographic characteristics.8
With regard to the association between the number of sex partners and HPV vaccination, either no association or a lower number of sexual partners among vaccinated females was found. A US study did not observe a difference in the mean number of reported lifetime partners (2.6 vs 3.0), or the number of sexual partners in the past year (2.57 vs 2.84) or the past 2 months (1.19 vs 1.44) between the vaccinated and unvaccinated participants.14 These findings were confirmed in other US cross- sectional studies that examined a relation with the number of lifetime sexual partners.10,11,19 A longitudinal study showed no association with the total number of partners; the respective change scores for vaccinated and unvaccinated groups were 0.31 and 0.25.16
There have been no associations found between HPV vaccination and consistent condom use. In fact, several studies found that among sexually active females, those who had had HPV vaccinations were more likely to use a condom.10,14,15 In contrast, a Dutch observational cohort study of almost 3000 adolescent girls aged 16 to 17 who were eligible for a catch-up HPV immunization campaign found that vaccinated adolescents were less likely to report always using a condom with their steady partner than unvaccinated adolescents were (odds ratio of 0.71, 95% CI 0.57 to 0.89). However, with casual partners condom usage was similar among the vaccinated and unvaccinated groups.8 A UK longitudinal study did not find a difference in condom use between vaccinated and unvaccinated adolescent girls.16
Conclusion
Within the existing limitations of currently available studies, HPV vaccination has not been associated with increased sexual risk behaviour in young females. For future studies exploring a possible relation between HPV vaccination and sexual behaviour, the focus should be on a longitudinal design that includes a baseline measurement of sexual behaviour before vaccination, that adjusts for possible confounders, and that measures both clinical indicators (STIs and pregnancy) and behavioural outcomes.
Notes
Child Health Update is produced by the Pediatric Research in Emergency Therapeutics (PRETx) program (www.pretx.org) at the BC Children’s Hospital in Vancouver, BC. Drs Donken, Ogilvie, Bettinger, and Sadarangani are members and Dr Goldman is Director of the PRETx program. The mission of the PRETx program is to promote child health through evidence-based research in therapeutics in pediatric emergency medicine.
Do you have questions about the effects of drugs, chemicals, radiation, or infections in children? We invite you to submit them to the PRETx program by fax at 604 875-2414; they will be addressed in future Child Health Updates. Published Child Health Updates are available on the Canadian Family Physician website (www.cfp.ca).
Footnotes
Competing interests
Dr Sadarangani has been an investigator on research grants from Pfizer, Merck, and VBI Vaccines but he has received no personal payments, with all monies paid to his institution.
- Copyright© the College of Family Physicians of Canada